FDA peptides panel includes doctors with ties to industry

Key Points:

• The FDA will hold a meeting next month to reconsider the safety and effectiveness of several popular peptide injections, with a new panel primarily composed of doctors and pharmacists who have financial ties to the peptide industry.
• These peptides, often promoted for muscle building, injury healing, and anti-aging, lack substantial scientific evidence and are frequently sold as "for research use only" to circumvent FDA regulations.
• Previous FDA panels, made up mostly of academic experts, had voted against approving these peptides due to safety concerns, but the new panel includes industry proponents who run clinics and pharmacies specializing in these unapproved therapies.
• The shift in panel composition aligns with Health Secretary Robert F. Kennedy Jr.'s efforts to reshape U.S. health policy under the Make America Healthy Again movement, which has faced criticism for promoting unapproved and potentially illegal drugs.
• Kennedy and his allies have previously criticized federal expert panels for alleged conflicts of interest, yet the new FDA advisory panels include members with disclosed financial interests in the peptide market, raising concerns about regulatory impartiality.